Therefore, our results suggest that MYBL1 functions as a critical pro-angiogenic factor in HCC by performing both in vitro and in vivo approaches, and that MYBL1 may represent a novel prognostic biomarker and anti-angiogenesis target for HCC patients. The gene discussed is MYBL1; the disease is hepatocellular carcinoma.